Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Demetrios Konstas

Neurology Tampa, FL Medical Doctor

NPI 1124394382 CMS profile 1399323

2816 W Virginia Ave, Mod D, Tampa, FL 33607

Open in the dashboard

General payments

$3,985

161 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Demetrios Konstas of Tampa, FL is reported in the CMS Open Payments database as having received $3,985 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $690 2
2023 General $78 1
2022 General $207 2
2020 General $800 47
2019 General $2,210 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Demetrios Konstas
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Demetrios Konstas were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Demetrios Konstas Neurology median Middle half National median
2019 $2,210 $474 $118–$2,177 $163
2020 $800 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $207 $442 $103–$2,388 $149
2023 $78 $464 $119–$2,312 $160
2024 $690 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. TG Therapeutics, Inc. $690 2 payments
  2. Biogen, Inc. $584 14 payments
  3. EMD Serono, Inc. $398 14 payments
  4. Allergan Inc. $391 27 payments
  5. Genzyme Corporation $270 15 payments
  6. Novartis Pharmaceuticals Corporation $220 14 payments
  7. Adamas Pharmaceuticals, Inc. $142 7 payments
  8. Arbor Pharmaceuticals, Inc. $128 7 payments
  9. Upsher-Smith Laboratories LLC $108 6 payments
  10. Amgen Inc. $97 5 payments
  11. Other $958 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,183 155 payments
  2. Consulting Fee $715 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $86 4 payments
Products named General payments · program years 2019–2024
  1. BRIUMVI $690 2 payments
  2. BOTOX $311 21 payments
  3. TECFIDERA $253 9 payments
  4. TYSABRI $239 6 payments
  5. AIMOVIG $148 8 payments
  6. GOCOVRI $142 7 payments
  7. GILENYA $111 7 payments
  8. Mavenclad $111 7 payments
  9. QUDEXY XR Topiramate Extended Release Capsules $108 6 payments
  10. AUBAGIO $106 6 payments
  11. Other $1,729 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record